Analysis
SK Hynix's strong Nasdaq debut -- a 13% first-day pop on a $26.5 billion raise, the largest-ever US listing by a non-American company -- is the freshest data point in a year that's about to face a much bigger test of public-market appetite for AI-adjacent listings: OpenAI and Anthropic are both racing toward their own IPOs, potentially within months of each other.
OpenAI has confidentially filed for a listing with Goldman Sachs, Morgan Stanley and JPMorgan as underwriters, targeting a debut as soon as September 2026 at a private-market valuation in the $730-850 billion range -- with some analysts expecting the actual public listing to push the company past a $1 trillion market capitalization once trading begins. Anthropic filed its own confidential S-1 in June, and while its most recent primary round valued the company at $965 billion, secondary-market trading has since pushed its implied valuation to $1.2 trillion, surpassing OpenAI's own secondary mark for the first time.
If both labs list anywhere near their current private or secondary valuations, the combined public-market value of the two companies would exceed $2 trillion -- a scale of simultaneous AI-lab listings that has no real precedent. The closest comparison is SpaceX's own roughly $1.77 trillion IPO earlier in 2026, still the largest in history, which demonstrated that public markets will absorb an enormous, single-company AI-adjacent listing without demand collapsing under the sheer size of the deal.
SK Hynix's successful debut this week matters as a leading indicator specifically because it's a physical-infrastructure company, not a software-first AI lab -- its strong reception suggests investor appetite for AI-adjacent listings extends beyond the marquee model-layer names to the memory, chip and infrastructure businesses underneath them. That's a genuinely bullish signal for how OpenAI and Anthropic's own listings might be received, since it shows demand isn't narrowly concentrated in one part of the AI stack.
For VCs and growth investors holding pre-IPO positions in either lab, the sequencing question matters enormously: whichever company lists first will set the pricing benchmark the second must either beat or explain away, turning what might otherwise be two independent listings into a genuine competitive event. For public-market investors, the sheer scale of capital these two listings could absorb -- potentially over $2 trillion combined -- raises real questions about whether the market has enough incremental demand to support both without one cannibalizing appetite for the other.
The bear case: private and secondary valuations built during a scarcity-driven bull run don't always survive contact with actual IPO price discovery, and both labs' current marks assume continued hypergrowth that any deceleration -- whether from increased competition, regulatory action, or a broader AI-spending slowdown -- could meaningfully compress. What to watch next: which lab actually lists first, and whether SK Hynix's strong reception this week holds up through its first full month of trading as a read on sustained investor appetite heading into the bigger AI-lab listings.
